Onkos Surgical to Acquire Juvenile Tumor System from Stryker
Onkos Surgical today announced that it has agreed to acquire the Juvenile Tumor System (JTS) from Stryker (NYSE: SYK).
Onkos, based in Parsippany, New Jersey, has reached a definitive agreement with the orthopedic technology giant on the system designed to enable limb stabilization and growth in pediatric patients with bone cancers, severe arthropathy , severe trauma, revisions, oncology and malignant diseases.
Financial terms of the transaction were not disclosed.
Onkos, which specializes in solutions for musculoskeletal oncology and other complex orthopedic conditions, said in a press release that the JTS enables non-invasive post-operative implant lengthening over time. in a clinical setting.
The design of the JTS eliminates the need for multiple lengthening, anesthesia, or sedation surgeries, helping to reduce the risk of complications and costs associated with limb reconstruction surgery.
“This is an important day for Onkos Surgical and the musculoskeletal oncology community,” Onkos Co-Founder and CEO Patrick Tracy said in version. “Our ‘why’ has always driven us to specifically address the many clinical challenges this community of surgeons and patients face on a daily basis. Pediatric cancer surgery and limb lengthening are complex and difficult procedures, and the STC the expandable prosthesis is a solution in the service of this mission.
“We are committed to being good stewards of technology. We are proud to partner with this community of dedicated surgeons and excited to create a bright future for technology as we continue this meaningful work for pediatric patients with musculoskeletal cancer.